5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro

The coronavirus disease 2019 (COVID 19) pandemic continues to pose a threat to global health. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) has spread rapidly worldwide and became dominant in many countries. A natural 5-aminolevulinic acid (5-ALA) with...

Descripción completa

Detalles Bibliográficos
Autores principales: Ngwe Tun, Mya Myat, Sakura, Takaya, Sakurai, Yasuteru, Kurosaki, Yohei, Inaoka, Daniel Ken, Shioda, Norifumi, Smith, Chris, Yasuda, Jiro, Morita, Kouichi, Kita, Kiyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043503/
https://www.ncbi.nlm.nih.gov/pubmed/35477500
http://dx.doi.org/10.1186/s41182-022-00422-7
_version_ 1784694894986526720
author Ngwe Tun, Mya Myat
Sakura, Takaya
Sakurai, Yasuteru
Kurosaki, Yohei
Inaoka, Daniel Ken
Shioda, Norifumi
Smith, Chris
Yasuda, Jiro
Morita, Kouichi
Kita, Kiyoshi
author_facet Ngwe Tun, Mya Myat
Sakura, Takaya
Sakurai, Yasuteru
Kurosaki, Yohei
Inaoka, Daniel Ken
Shioda, Norifumi
Smith, Chris
Yasuda, Jiro
Morita, Kouichi
Kita, Kiyoshi
author_sort Ngwe Tun, Mya Myat
collection PubMed
description The coronavirus disease 2019 (COVID 19) pandemic continues to pose a threat to global health. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) has spread rapidly worldwide and became dominant in many countries. A natural 5-aminolevulinic acid (5-ALA) with sodium ferrous citrate (SFC) has demonstrated antiviral activity in Wuhan, Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 infections in vitro. In this study, we report antiviral activity of 5-ALA, 5-ALA with SFC led to IC(50) of 329 and 765/191, respectively after infection with Omicron variant of SARS-CoV-2 in vitro. Our finding suggests that 5-ALA could be used as antiviral drug candidate to treat Omicron variant infected patients.
format Online
Article
Text
id pubmed-9043503
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90435032022-04-27 5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro Ngwe Tun, Mya Myat Sakura, Takaya Sakurai, Yasuteru Kurosaki, Yohei Inaoka, Daniel Ken Shioda, Norifumi Smith, Chris Yasuda, Jiro Morita, Kouichi Kita, Kiyoshi Trop Med Health Letter to the Editor The coronavirus disease 2019 (COVID 19) pandemic continues to pose a threat to global health. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) has spread rapidly worldwide and became dominant in many countries. A natural 5-aminolevulinic acid (5-ALA) with sodium ferrous citrate (SFC) has demonstrated antiviral activity in Wuhan, Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 infections in vitro. In this study, we report antiviral activity of 5-ALA, 5-ALA with SFC led to IC(50) of 329 and 765/191, respectively after infection with Omicron variant of SARS-CoV-2 in vitro. Our finding suggests that 5-ALA could be used as antiviral drug candidate to treat Omicron variant infected patients. BioMed Central 2022-04-27 /pmc/articles/PMC9043503/ /pubmed/35477500 http://dx.doi.org/10.1186/s41182-022-00422-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Letter to the Editor
Ngwe Tun, Mya Myat
Sakura, Takaya
Sakurai, Yasuteru
Kurosaki, Yohei
Inaoka, Daniel Ken
Shioda, Norifumi
Smith, Chris
Yasuda, Jiro
Morita, Kouichi
Kita, Kiyoshi
5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro
title 5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro
title_full 5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro
title_fullStr 5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro
title_full_unstemmed 5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro
title_short 5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro
title_sort 5-aminolevulinic acid antiviral efficacy against sars-cov-2 omicron variant in vitro
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043503/
https://www.ncbi.nlm.nih.gov/pubmed/35477500
http://dx.doi.org/10.1186/s41182-022-00422-7
work_keys_str_mv AT ngwetunmyamyat 5aminolevulinicacidantiviralefficacyagainstsarscov2omicronvariantinvitro
AT sakuratakaya 5aminolevulinicacidantiviralefficacyagainstsarscov2omicronvariantinvitro
AT sakuraiyasuteru 5aminolevulinicacidantiviralefficacyagainstsarscov2omicronvariantinvitro
AT kurosakiyohei 5aminolevulinicacidantiviralefficacyagainstsarscov2omicronvariantinvitro
AT inaokadanielken 5aminolevulinicacidantiviralefficacyagainstsarscov2omicronvariantinvitro
AT shiodanorifumi 5aminolevulinicacidantiviralefficacyagainstsarscov2omicronvariantinvitro
AT smithchris 5aminolevulinicacidantiviralefficacyagainstsarscov2omicronvariantinvitro
AT yasudajiro 5aminolevulinicacidantiviralefficacyagainstsarscov2omicronvariantinvitro
AT moritakouichi 5aminolevulinicacidantiviralefficacyagainstsarscov2omicronvariantinvitro
AT kitakiyoshi 5aminolevulinicacidantiviralefficacyagainstsarscov2omicronvariantinvitro

Ejemplares similares